Disease mechanisms and clonidine treatment in adolescent chronic fatigue syndrome a combined cross-sectional and randomized clinical trial

JAMA Pediatrics

Volumn 168, Issue 4, 2014, Pages 351-360

  Sulheim, Dag ^a,b   Fagermoen, Even ^a,c   Winger, Anette ^c,d   Andersen, Anders Mikal ^a   Godang, Kristin ^e   Muller, Fredrik ^a   Rowe, Peter C ^f   Saul, J Philip ^g   Skovlund, Eva ^h,i   Oie, Merete Glenne ^h,j   Bruun, Vegard W ^a,c,k  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b Lillehammer Co Hosp Lillehammer S   (Norway)

^c UNIVERSITY OF OSLO   (Norway)

^d OSLO METROPOLITAN UNIVERSITY   (Norway)

^e OSLO UNIVERSITY HOSPITAL   (Norway)

^f JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^h UNIVERSITY OF OSLO   (Norway)

ⁱ NORWEGIAN INSTITUTE OF PUBLIC HEALTH   (Norway)

^j INNLANDET HOSPITAL TRUST   (Norway)

^k AKERSHUS UNIVERSITY HOSPITAL   (Norway)

more..

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; CLONIDINE; CREATININE; HYDROCORTISONE; NORADRENALIN;

ADOLESCENT; ARTICLE; CHRONIC FATIGUE SYNDROME; CONTROLLED STUDY; CREATININE URINE LEVEL; CROSS-SECTIONAL STUDY; DISEASE ASSOCIATION; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG CAPSULE; DRUG MONITORING; DUODENUM ULCER; FAINTNESS; FEMALE; HEART RATE; HUMAN; HYDROCORTISONE URINE LEVEL; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; INFLAMMATION; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NORADRENALIN BLOOD LEVEL; NORWAY; PATHOPHYSIOLOGY; PATIENT COMPLIANCE; PEPTIC ULCER; PHYSICAL ACTIVITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SOMNOLENCE; SYMPATHETIC TONE; TREATMENT DURATION; TREATMENT OUTCOME;

ADOLESCENT; ADRENERGIC ALPHA-2 RECEPTOR AGONISTS; C-REACTIVE PROTEIN; CLONIDINE; CREATININE; CROSS-SECTIONAL STUDIES; DOUBLE-BLIND METHOD; FATIGUE SYNDROME, CHRONIC; FEMALE; HUMANS; HYDROCORTISONE; MALE; NOREPINEPHRINE; NORWAY; SYMPATHETIC NERVOUS SYSTEM; TREATMENT OUTCOME;

EID: 84898472854     PISSN: 21686203     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamapediatrics.2013.4647     Document Type: Article

References (49)

1. Fukuda K, Straus SE, Hickie I, Sharpe MC, Dobbins JG, Komaroff A; International Chronic Fatigue Syndrome Study Group. The chronic fatigue syndrome: a comprehensive approach to its definition and study. Ann Intern Med. 1994;121(12):953-959.
2. Royal College of Paediatrics and Child Health. Evidence Based Guidelines for the Management of CFS/ME (Chronic Fatigue Syndrome/Myalgic Encephalopathy) in Children and Young Adults. London, England: Royal College of Paediatrics and Child Health; 2004.
3. Kennedy G, Underwood C, Belch JJ. Physical and functional impact of chronic fatigue syndrome/myalgic encephalomyelitis in childhood. Pediatrics. 2010;125(6):e1324-e1330. doi:10.1542/peds.2009-2644.
4. Missen A, HollingworthW, Eaton N, Crawley E. The financial and psychological impacts on mothers of children with chronic fatigue syndrome (CFS/ME). Child Care Health Dev. 2012;38(4):505-512.
5. Nijhof SL, Maijer K, Bleijenberg G, Uiterwaal CS, Kimpen JL, van de Putte EM. Adolescent chronic fatigue syndrome: prevalence, incidence, and morbidity. Pediatrics. 2011;127(5):e1169-e1175. doi:10.1542/peds.2010-1147.
6. Crawley EM, Emond AM, Sterne JA. Unidentified chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME) is a major cause of school absence: surveillance outcomes from school-based clinics. BMJ Open. 2011;1(2): e000252. doi:10.1136/bmjopen-2011-000252.
7. Jason LA, Bell DS, Rowe K, et al. A pediatric case definition for chronic fatigue syndrome. J Chronic Fatigue Syndr. 2006;13(2-3):1-44.
8. Nijhof SL, Bleijenberg G, Uiterwaal CS, Kimpen JL, van de Putte EM. Effectiveness of internet-based cognitive behavioural treatment for adolescents with chronic fatigue syndrome (FITNET): a randomised controlled trial. Lancet. 2012;379(9824):1412-1418.
9. Wyller VB, Due R, Saul JP, Amlie JP, Thaulow E. Usefulness of an abnormal cardiovascular response during low-grade head-up tilt-test for discriminating adolescents with chronic fatigue from healthy controls. Am J Cardiol. 2007;99(7):997-1001.
10. Wyller VB, Barbieri R, Thaulow E, Saul JP. Enhanced vagal withdrawal duringmild orthostatic stress in adolescents with chronic fatigue. Ann Noninvasive Electrocardiol. 2008;13(1):67-73.
11. Wyller VB, Godang K, Morkrid L, Saul JP, Thaulow E,Walloe L. Abnormal thermoregulatory responses in adolescents with chronic fatigue syndrome: relation to clinical symptoms. Pediatrics. 2007;120(1):e129-e137. doi:10.1542/peds.2006 -2759.
12. Wyller VB, Helland IB. Relationship between autonomic cardiovascular control, case definition, clinical symptoms, and functional disability in adolescent chronic fatigue syndrome: an exploratory study. Biopsychosoc Med. 2013;7(1):5. doi:10.1186/1751-0759-7-5.
13. Klimas NG, Broderick G, Fletcher MA. Biomarkers for chronic fatigue. Brain Behav Immun. 2012;26(8):1202-1210.
14. Raison CL, Lin JM, Reeves WC. Association of peripheral inflammatory markers with chronic fatigue in a population-based sample. Brain Behav Immun. 2009;23(3):327-337.
15. Papadopoulos AS, Cleare AJ. Hypothalamicpituitary- adrenal axis dysfunction in chronic fatigue syndrome. Nat Rev Endocrinol. 2012;8(1):22-32.
16. Segal TY, Hindmarsh PC, Viner RM. Disturbed adrenal function in adolescents with chronic fatigue syndrome. J Pediatr Endocrinol Metab. 2005;18(3):295-301.
17. Majer M, Welberg LA, Capuron L, Miller AH, Pagnoni G, Reeves WC. Neuropsychological performance in persons with chronic fatigue syndrome: results from a population-based study. Psychosom Med. 2008;70(7):829-836.
18. DeLuca J, Johnson SK, Ellis SP, Natelson BH. Cognitive functioning is impaired in patients with chronic fatigue syndrome devoid of psychiatric disease. J Neurol Neurosurg Psychiatry. 1997;62(2):151-155.
19. Haig-Ferguson A, Tucker P, Eaton N, Hunt L, Crawley E. Memory and attention problems in children with chronic fatigue syndrome or myalgic encephalopathy. Arch Dis Child. 2009;94(10): 757-762.
20. Wyller VB, Eriksen HR, Malterud K. Can sustained arousal explain the chronic fatigue syndrome? Behav Brain Funct. 2009;5:10. doi:10.1186/1744-9081-5- 10.
21. Maloney EM, Boneva R, Nater UM, Reeves WC. Chronic fatigue syndrome and high allostatic load: results from a population-based case-control study in Georgia. Psychosom Med. 2009;71(5):549-556.
22. McEwen BS. Protective and damaging effects of stress mediators: central role of the brain. Dialogues Clin Neurosci. 2006;8(4):367-381.
23. Ursin H, Eriksen HR. Sensitization, subjective health complaints, and sustained arousal.Ann N Y Acad Sci. 2001;933:119-129.
24. Kadota Y, Cooper G, Burton AR, et al. Autonomic hyper-vigilance in post-infective fatigue syndrome. Biol Psychol. 2010;85(1):97-103.
25. Hickie I, Davenport T,Wakefield D, et al; Dubbo Infection Outcomes Study Group. Post-infective and chronic fatigue syndromes precipitated by viral and non-viral pathogens: prospective cohort study. BMJ. 2006;333(7568):575-581.
26. Katz BZ, Shiraishi Y, Mears CJ, Binns HJ, Taylor R. Chronic fatigue syndrome after infectious mononucleosis in adolescents. Pediatrics. 2009;124(1):189-193.
27. Szabo B. Imidazoline antihypertensive drugs: a critical review on their mechanism of action. Pharmacol Ther. 2002;93(1):1-35.
28. Cividjian A, Toader E,Wesseling KH, Karemaker JM, McAllen R, Quintin L. Effect of clonidine on cardiac baroreflex delay in humans and rats. Am J Physiol Regul Integr Comp Physiol. 2011;300(4): R949-R957.
29. Kim MH, Hahn TH. The effect of clonidine pretreatment on the perioperative proinflammatory cytokines, cortisol, and ACTH responses in patients undergoing total abdominal hysterectomy. Anesth Analg. 2000;90(6):1441-1444.
30. Kim S, Bobeica I, Gamo NJ, Arnsten AF, Lee D. Effects of ?-2A adrenergic receptor agonist on time and risk preference in primates. Psychopharmacology (Berl). 2012;219(2):363-375.
31. Morriss RK, Robson MJ, Deakin JF. Neuropsychological performance and noradrenaline function in chronic fatigue syndrome under conditions of high arousal. Psychopharmacology (Berl). 2002;163(2):166-173.
32. National Institute for Health and Clinical Excellence. Chronic Fatigue Syndrome/Myalgic Encephalomyelitis (or Encephalopathy): Diagnosis and Management of CFS/ME in Adults and Children: NICE Clinical Guideline. No.53. London, England: National Institute for Health and Clinical Excellence; 2007.
33. Sulheim D, Hurum H, Helland IB. Adolescent chronic fatigue syndrome; a follow-up study displays concurrent improvement of circulatory abnormalities and clinical symptoms. Biopsychosoc Med. 2012;6:10. doi:10.1186/1751-0759-6-10.
34. ICH Topic E 9: Statistical Principles for Clinical Guidelines. London, England: European Medicines Agency; 1998.
35. Anavekar SN, Howes LG, Jarrott B, Syrjanen M, Conway EL, Louis WJ. Pharmacokinetics and antihypertensive effects of low dose clonidine during chronic therapy. J Clin Pharmacol. 1989;29(4):321-326.
36. Veith RC, Best JD, Halter JB. Dose-dependent suppression of norepinephrine appearance rate in plasma by clonidine in man. J Clin Endocrinol Metab. 1984;59(1):151-155.
37. Fagermoen E, Sulheim D,Winger A, et al. Clonidine in the treatment of adolescent chronic fatigue syndrome: a pilot study for the NorCAPITAL trial. BMC Res Notes. 2012;5:418. doi:10.1186 /1756-0500-5-418.
38. Strycker LA, Duncan SC, Chaumeton NR, Duncan TE, Toobert DJ. Reliability of pedometer data in samples of youth and older women. Int J Behav Nutr Phys Act. 2007;4:4. doi:10.1186 /1479-5868-4-4.
39. Newton JL, Pairman J, Hallsworth K, Moore S, Plotz T, Trenell MI. Physical activity intensity but not sedentary activity is reduced in chronic fatigue syndrome and is associated with autonomic regulation. QJM. 2011;104(8):681-687.
40. Daviss WB, Birmaher B, Melhem NA, Axelson DA, Michaels SM, Brent DA. Criterion validity of the Mood and Feelings Questionnaire for depressive episodes in clinic and non-clinic subjects. J Child Psychol Psychiatry. 2006;47(9):927-934.
41. Fletcher MA, Rosenthal M, Antoni M, et al. Plasma neuropeptide Y: a biomarker for symptom severity in chronic fatigue syndrome. Behav Brain Funct. 2010;6:76.
42. Ober K, Benson S, VogelsangM, et al. Plasma noradrenaline and state anxiety levels predict placebo response in learned immunosuppression. Clin Pharmacol Ther. 2012;91(2):220-226.
43. Cole SW, Arevalo JM, Takahashi R, et al. Computational identification of gene-social environment interaction at the human IL6 locus. ProcNatl Acad Sci U S A. 2010;107(12):5681-5686.
44. Rosas-BallinaM, Tracey KJ. The neurology of the immune system: neural reflexes regulate immunity. Neuron. 2009;64(1):28-32.
45. MaesM,Mihaylova I, Bosmans E. Not in the mind of neurasthenic lazybones but in the cell nucleus: patients with chronic fatigue syndrome have increased production of nuclear factor kappa beta. Neuro Endocrinol Lett. 2007;28(4):456-462.
46. Cameron B, Flamand L, Juwana H, et al. Serological and virological investigation of the role of the herpesviruses EBV, CMV and HHV-6 in post-infective fatigue syndrome. J Med Virol. 2010;82(10):1684-1688.
47. Thananopavarn C, Golub MS, Eggena P, Barrett JD, Sambhi MP. Clonidine, a centrally acting sympathetic inhibitor, as monotherapy for mild to moderate hypertension. Am J Cardiol. 1982;49(1):153-158.
48. Light AR, Bateman L, Jo D, et al. Gene expression alterations at baseline and following moderate exercise in patients with chronic fatigue syndrome and fibromyalgia syndrome. J Intern Med. 2012;271(1):64-81.
49. Bould H, Collin SM, Lewis G, Rimes K, Crawley E. Depression in paediatric chronic fatigue syndrome. Arch Dis Child. 2013;98(6):425-428.